Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terrence Brogan

Dermatology Indianapolis, IN Medical Doctor

NPI 1760641724 CMS profile 641419

8925 N Meridian St Ste 200, Indianapolis, IN 46260

Open in the dashboard

General payments

$2,270

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terrence Brogan of Indianapolis, IN is reported in the CMS Open Payments database as having received $2,270 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,148 51
2024 General $900 52
2023 General $188 10
2019 General $34 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terrence Brogan
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Terrence Brogan were reported at $1,148. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Terrence Brogan Dermatology median Middle half National median
2019 $34 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $188 $607 $159–$1,674 $160
2024 $900 $751 $204–$1,903 $164
2025 $1,148 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $588 35 payments
  2. Amgen Inc. $284 13 payments
  3. AbbVie, Inc. $242 14 payments
  4. Novartis Pharmaceuticals Corporation $205 7 payments
  5. Regeneron Healthcare Solutions, Inc. $193 7 payments
  6. Janssen Biotech, Inc. $161 7 payments
  7. Incyte Corporation $126 5 payments
  8. Pfizer Inc. $107 6 payments
  9. LEO Pharma Inc. $73 4 payments
  10. UCB, Inc. $63 3 payments
  11. Other $229 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,006 111 payments
  2. Education $264 4 payments
Products named General payments · program years 2019–2025
  1. ILUMYA $313 24 payments
  2. Otezla $284 13 payments
  3. TREMFYA $161 7 payments
  4. DUPIXENT $129 3 payments
  5. OPZELURA $126 5 payments
  6. LITFULO $107 6 payments
  7. CIBINQO $107 6 payments
  8. RINVOQ $101 7 payments
  9. EUCRISA $90 5 payments
  10. SKYRIZI $82 4 payments
  11. Other $945 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,068

Median for Dermatology: 534

Drug cost

$292,899

Median for Dermatology: $67,151

Branded share of claims

7.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $101,027
Otezla Apremilast Brand 20 $95,096
Humira(Cf) Pen Adalimumab Brand 12 $78,058
Clobetasol Propionate Generic 131 $5,197
Metronidazole Generic 47 $2,548
Ketoconazole Generic 199 $2,511
Triamcinolone Acetonide Generic 254 $2,193
Doxycycline Hyclate Generic 59 $1,124
Doxycycline Monohydrate Generic 37 $992
Ammonium Lactate Generic 40 $960

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$274,368

Of which drugs: $15,912

Medicare patients

1,313

Average age 75

Services billed

7,438

461 women, 852 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 40%
Ischemic heart disease 29%
Diabetes 20%
Cancer 19%
Atrial fibrillation 15%
Chronic kidney disease 15%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 47 52 $15,903

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $151
$151 20 —
OPZELURA
  • Incyte Corporation $126
$126 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $89
$89 — —
RINVOQ
  • AbbVie, Inc. $79
$79 — —
SKYRIZI
  • AbbVie, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record